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Commentary
U.S. President Barack Obama recently announced a new Precision Medicine Initiative, and Drs.
Francis Collins and Harold Varmus have begun to provide a vision for how some of this initiative
might be implemented by the U.S. National Institutes of Health (NIH) (1). Precision medicine
may be defined as “an emerging approach for disease treatment and prevention that takes into
account individual variability in genes, environment, and lifestyle for each person” (2). A vision
of the NIH portion of the Precision Medicine Initiative is to launch a large-scale national cohort
study of a Million or more Americans to advance understanding of how to optimize treatments
customized to individual variability in genomic and environmental health-determinants (2). A
precision-medicine approach, using shared-decision making with patients and their providers
as partners in patient-centered care, offers an important opportunity to improve substance-use
disorders (SUDs) prevention and treatment outcomes (3, 4). Pertinent to precision medicine,
the Collaborative Research on Addictions at NIH, comprising the National Institute on Drug
Abuse, National Institute on Alcohol Abuse and Alcoholism, and the National Cancer Institute,
in partnership with other NIH Institutes, Centers and Offices, is currently planning to launch a
longitudinal cohort study of Adolescent Brain and Cognitive Development (ABCD). This study
will follow 10,000 youth over up to a 10-year period, approximately ages 9–10 at baseline when
largely naïve to use of alcohol, marijuana, nicotine, and other drugs. This national cohort study
presents a key opportunity to answer fundamentally important questions to informing a precision-
medicine approach regarding prevention of SUDs in youth (5). Several relevant questions are:
(1) how does repeated exposure to abused substances, such as nicotine, alcohol, and cannabis,
impact normative brain development essential for memory and cognitive functioning? (2) How
do drug-altered brain-maturation pathways inform precision-medicine-tailored SUDs prevention
approaches targeting high-risk youth? (3) Which brain-development events altered following ado-
lescent drug use heighten likelihood of transformation of unhealthy drug use into full-blown SUDs
in subpopulations with, or without, co-occurring mental health disorders? (4) How do drug-
induced alterations in brain-development and memory impairments interact with genomic and
epigenetic risk factors in these different subpopulations to increase vulnerability to SUDs? (5) In
what manner does use of specific substances impact use of other substances? Thus, the objective
of the ABCD study is timely to precision medicine: to better understand how exposure to abused
substances modifies brain-development trajectories and how this relates to emotional and mental
health, social development, memory and other cognitive function, as well as academic and other
outcomes (5).
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Numerous studies suggest that heavy substance use during
childhood and adolescence influences long-term brain and cogni-
tive development and heightens risks for SUDs and co-occurring
mental disorders (6–9). Therefore, it is critical to recruit youth
in the early, pre-symptomatic phase in order to measure mental
health and psychosocial factors over time to understand how they
contribute to observed changes in brain and cognitive develop-
ment (5).To inform how clinicians may optimally intervene early
to prevent escalation of unhealthy drug use in youth, this research
will prospectively identify and characterize developmental pro-
cesses across behavioral, cognitive, and neurobiological domains
that give rise to transitions between hazardous substance use and
SUDs trajectories in diverse populations of youth. Such longi-
tudinal research will also evaluate how critical factors mediate
or modify these relationships during sensitive brain-development
windows. In such a large-scale longitudinal cohort study, an
important consideration will be to implement a sampling strategy
which includes a community-based sample that is broadly repre-
sentative of the U.S. general population. Biospecimens will also be
collected for subsequent genomic/epigenomic and other analyses
in future research studies.
The ABCD study will leverage latest brain imaging advances,
bioinformatics methods for analyzing biomedical big data, and
electronic health records information to determine how sub-
stance use affects brain-development trajectories, relevant gene-
environment interactions, memory capabilities, mental disorders,
and other medical and functional outcomes. Another considera-
tion is achieving sufficient statistical power and comprehensive
controls to account for the many possible confounds in which
youth who choose to frequently use alcohol or other drugs might
also have other co-occurring problems either naturally or due to
other lifestyle choices or circumstances. The ABCD study will also
carefully characterize and control for socio-demographic, prenatal
drug exposure, drug availability, family history, physical or sexual
abuse, head trauma, behavioral, and other environmental risk
factors (5).
Open data sharing and safeguarding privacy need to be corner-
stones for such lines of research, to build a trustworthy scientific
knowledge base and support a national network of scientists with
innovative precision-medicine approaches to SUDs prevention
and treatment. Collected genetic biospecimens need to be appro-
priately paired with other relevant health information and suitably
processed, curated, and stored, in a manner whereby informed
consent is obtained consistent with allowing participants’ permis-
sion for their future research use. Furthermore, to maintain high-
quality repositories of biomedical big data, such research areas
would need to develop sustainable operational and governance
standards and conform to industry best practices (10). Moreover,
to permit data sharing, procedures need to be put in place to
enable harmonization of data collection, querying, extraction,
and storage, across study sites with disparate electronic-health-
record-system standards and data structures. Standardization of
collected measures and data harmonization is needed to return
clinical data in a consistent manner to a centralized repository
and permit semanticmapping to achieve health information inter-
operability. The above research directions require a collaborative,
sustained national effort involving many scientists, clinicians, and
bioinformatics experts.
In summary, the ABCD study and similar research offer a valu-
able opportunity to informprecision-medicine research on how to
leverage bioinformatics advances in genomics andhealth informa-
tion technology to guide customization of molecular, clinical, and
environmental information toward optimizing SUD-prevention
in youth. Findings from such research may also guide precision
medicine through systematic identification of risk/protective fac-
tors, biomarkers, and individual variations in these, which crit-
ically mediate effects of substance use on the trajectory of the
developing brain, memory, and other cognitive areas in youth.
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